PatientsVille.com Logo


TROCAR Medical Research Studies

Up-to-date List of TROCAR Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest TROCAR Medical Research Studies

Rank Status Study
1 Recruiting Are Serial Electrocardiograms Additive to SeriAl Second-generations Troponins in Predicting Acute CoronAry Syndromes in PatienTs With Undifferentiated cHest Pain
Conditions: Acute Coronary Syndrome;   Chest Pain
Intervention: Device: Serial Electrocardiograms
Outcome Measures: Major Adverse Cardiovascular Events at 30 days;   Evidence of acute myocardial ischemia via objective cardiac testing performed during the index hospitalization
2 Unknown  PhysioGlove Versus Clinic Electrocardiogram Comparison
Conditions: Patients With Normal ECG;   Patients With Pathological ECG
Outcome Measure: Comparison of the technical and diagnostic quality of outpatient clinic Electrocardiogram with the on-site (cardiology consultation clinic) performed Electrocardiograms
3 Not yet recruiting Six Lead Identification of Atrial Fibrillation
Conditions: Atrial Fibrillation;   Atrial Flutter;   Bradycardia;   Tachycardia;   Tachycardia, Supraventricular
Intervention: Device: RhythmPadGP
Outcome Measures: Number of participants with a diagnosis of Atrial Fibrillation;   Number of participants with a diagnosis of atrial flutter;   Number of participants with a diagnosis of tachycardia (heart rate greater the 100 beats per minute);   Number of participants with a diagnosis of bradycardia (heart rate less then 50 beats per minute);   Accurate diagnosis of supraventricular tachycardia;   Number of participants with a diagnosis of atrial or ventricular ectopy
4 Unknown  Prevalence of Chagas Disease in Immigrant Patients With Conduction Abnormalities on Electrocardiogram
Condition: Chagas Disease
Intervention: Procedure: Trypanosoma cruzi serology
Outcome Measure: Prevalence of positive trypanosoma cruzi serologies
5 Recruiting Markers of Paroxysmal Atrial Fibrillation in Esophageal Holter Electrocardiography
Conditions: Atrial Fibrillation;   Atrial Premature Complexes
Outcome Measures: Number atrial premature beats not conducted to the ventricles;   Mean duration of the p-eso-wave;   Mean duration of the left atrial wavefront;   p-eso-wave-duration-dispersion;   mean number of p-eso-wave-peaks;   root mean square voltages of the last 20 ms of the p-eso-wave in the esophageal ECG
6 Unknown  Cerebral Artery Stenosis, Coronary Artery Disease and Arrhythmia
Conditions: Stroke;   Coronary Artery Disease;   Arrhythmia
Intervention: Procedure: Digital subtraction angiography and 24-hour simultaneous recorder of electrocardiograph
Outcome Measure:
7 Not yet recruiting A Study to Evaluate the Effects of JNJ-54861911 on Electrocardiogram Intervals in Healthy Particiants
Condition: Healthy
Interventions: Drug: JNJ-54861911-Therapeutic Dose;   Drug: JNJ-54861911 - Supratherapeutic Dose;   Drug: JNJ-54861911-Matched Placebo;   Drug: Moxifloxacin;   Drug: Moxifloxacin Matched Placebo
Outcome Measures: Change From Baseline in QT/QTc interval at Day 7;   Change From Baseline in Other Electrocardiogram (ECG) Parameters at Day 7;   Maximum Plasma Concentration (C[max]ss) at Steady State;   Minimum Plasma Concentration (C[min]ss) at Steady State;   Trough Plasma Concentration (C[trough]);   Time to Reach the Maximum Plasma Concentration (T[max]);   Average Plasma Concentration at Steady State (C[avg]ss);   Area Under the Plasma Concentration-Time Curve During a Dosing Interval (AUC[tau]ss)
8 Not yet recruiting A Study to Evaluate the Effect of GSK1322322 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers
Condition: Infections, Bacterial
Interventions: Drug: GSK1322322 1200 mg;   Drug: GSK1322322 3000 mg;   Drug: Placebo;   Drug: Moxifloxacin
Outcome Measures: Change from baseline in QT duration corrected for heart rate by Fridericia's formula (QTcF) for GSK1322322 as compared with time-matched placebo;   Change from baseline in QT duration corrected for heart rate by Bazett's formula (QTcB), Individual (linear) QT correction (QTci), QT, and heart rate (HR);   Change from baseline in QTcB, QTci, QT, and HR;   Plasma concentrations and selected pharmacokinetic (PK) parameters of moxifloxacin;   Plasma concentrations and selected PK parameters of GSK1322322/moxifloxacin;   Safety and tolerability of GSK1322322 as assessed by change from baseline in 12-lead ECGs;   Safety and tolerability of GSK1322322 as assessed by change from baseline in vital signs;   Safety and tolerability of GSK1322322 as assessed by number of subjects with adverse events;   Safety and tolerability of GSK1322322 as assessed by change from baseline in toxicity grading of clinical laboratory tests
9 Recruiting Home Electrocardiogram (ECG) Monitoring After Heart Transplantation
Conditions: Cardiac Transplant Rejection;   Qt Interval, Variation in
Outcome Measures: number and grade of acute allograft rejection episodes;   all cause mortality
10 Unknown  Electrocardiography Versus Pulse Oximetry for Newborn Heart Rate Determination
Condition: Prematurity
Intervention: Device: Apparatuses
Outcome Measures: Time until accurate heart rate.;   Intermeasurement accuracy
11 Unknown  Electrocardiogram Variations in the Prediction of Development of Atrial Fibrillation
Condition: Adults Past 18years Old With Two Electrocardiogram
Outcome Measure: Variations (differences or deltas) between 2 standard ECG separated in time
12 Recruiting Fetal Electrocardiogram Extraction-Pilot Study
Condition: Pregnant Women
Outcome Measures: Beat-to-beat fetal heart rate will be compared to the Doppler result.;   Evaluate the presence of other fECG intervals.
13 Unknown  Time Frequency Analysis of Electrocardiogram and Blood Pressure in Intracranial Hemorrhage Patients
Conditions: Subarachnoid Hemorrhage;   Intracranial Hemorrhages;   Cerebral Hemorrhage
Outcome Measures: Activity of autonomic nervous activities determined by low frequency and high frequency energies in heart rate variability;   Presence of vasospasm or not
14 Recruiting Impact of Right Ventricular Pacing Determined by Electrocardiography
Condition: Atrioventricular Block
Interventions: Procedure: Septal pacing;   Procedure: Apex pacing
Outcome Measure: > 10% decrease of ejection fraction
15 Recruiting ECG Optimization of CRT: Evaluation of Mid-term Response
Condition: Heart Failure
Interventions: Other: Device programming: nominal;   Other: Programming optimization by QRS
Outcome Measures: Clinical response;   Echocardiographic response;   Pacing/sensing AV delay difference
16 Recruiting Personalized Risk Identification and Management for Arrhythmias and Heart Failure by ECG and MRI
Condition: General Hospital Population With Routine 12-lead ECG
Outcome Measure:
17 Recruiting Tryptase and Coronary Heart Disease
Conditions: Acute Coronary Syndrome With ST Elevation on Electrocardiogram;   Acute Coronary Syndrome Without ST Elevation on Electrocardiogram;   Noncritical Coronary Artery Disease With Coronary Stenosis <50%;   Aortic Aneurysms
Outcome Measures: serum level of tryptase as a biomarker in coronary;   Tryptase and major cardiovascular events
18 Not yet recruiting A Study to Determine the Feasibility of Wireless Electrocardiography
Conditions: Cardiac Rhythm Disturbances Including:;   Atrial Fibrillation;   Premature Atrial and Ventricular Beats;   Conduction Defects;   Normal Sinus Rhythm
Intervention: Device: Observational ambulatory ECG monitoring
Outcome Measure: Percent of 8 second ECG strips of sufficient quality for visual diagnosis
19 Recruiting The Leiden Nonischemic Cardiomyopathy Study
Conditions: Cardiomyopathy, Dilated;   Tachycardia, Ventricular;   Ventricular Fibrillation
Interventions: Other: Transthoracic echocardiography;   Other: Exercise test;   Other: 24-hour Holter Electrocardiogram;   Other: Contrast-enhanced magnetic resonance imaging;   Other: 123-iodine metaiodobenzylguanidine imaging;   Other: Blood samples;   Genetic: Genetic analysis;   Procedure: Invasive electrophysiological study;   Procedure: Endomyocardial biopsy;   Procedure: Intraoperative biopsy;   Procedure: Intraoperative mapping and/or ablation
Outcome Measures: Inducibility of ventricular arrhythmias;   Type of induced ventricular arrhythmias;   Spontaneous ventricular arrhythmias;   Type of spontaneous ventricular arrhythmias;   Hospital admissions for heart failure;   Cardiac mortality;   All-cause mortality;   LV function/dimensions/compact fibrosis deterioration as assessed by 123-I MIBG imaging and/or CE-MRI
20 Unknown  Safety of Amiodarone and Ranolazine Together in Patients With Angina
Conditions: Chronic Stable Angina;   Coronary Artery Disease;   Atrial Fibrillation;   Ventricular Tachycardia
Interventions: Drug: ranolazine;   Drug: placebo
Outcome Measures: ventricular arrhythmia;   atrial arrhythmia burden;   Electrocardiogram (EKG) corrected QT (QTc) interval measurement;   hospitalization;   syncope hospitalization;   liver function assay

These studies may lead to new treatments and are adding insight into TROCAR etiology and treatment.

A major focus of TROCAR research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss TROCAR